New studies to advance the science on CBD
use and athlete health and wellness and to drive product
development under new U.S. sports performance brand, ROAR
Sports
TSX: ACB | NYSE: ACB
LAS VEGAS, July 24, 2019 /CNW/ - Aurora Cannabis Inc.
("Aurora" or the "Company") (NYSE: ACB) (TSX: ACB), the Canadian
company that's defining the future of cannabis worldwide, and UFC,
the world's premier mixed martial arts organization, are proud to
announce the launch of a joint clinical research program that will
produce multiple studies under the terms of their recently
announced partnership.
The research will examine the use of hemp-derived CBD as an
effective treatment for pain, inflammation, wound-healing, and
recovery on MMA athletes.
The ground-breaking research partnership is aimed at
understanding key health and recovery needs of elite athletes in
such a highly physical and competitive sport as mixed martial arts.
Research data will then be used to drive the development of
science-backed, hemp-derived CBD topicals that will be safe and
reliable. These new products will help combat the rapidly growing
market of untested CBD treatments currently being used by
high-performance and non-professional athletes.
Once research is complete, any resulting product will come to
life in the U.S. under the new high-performance sports brand ROAR
Sports, a portfolio of high-quality, hemp-derived CBD topical
treatments scientifically formulated with elite athletes in mind.
Through analysis of athlete needs and scientific data, ROAR Sports
will challenge the status quo, seek to alleviate the stresses
of competition, and earn designation as the "Official CBD product
of UFC."
The multi-phase clinical study at the UFC Performance
Institute® in Las
Vegas will be led by Dr. Jason
Dyck, Chair of Aurora's Global Scientific Oversight
Committee; Dr. Kelly Narine,
Aurora's Vice President Global Research and Medical Affairs; and
the team of sports performance experts at the UFC Performance
Institute, led by Dr. Duncan French,
UFC Vice President of Performance. Using active UFC athletes on a
strictly voluntary basis, the study will help establish
peer-reviewed, publishable research in this area. Products will be
developed in full compliance with U.S. federal law and with UFC's
anti-doping program, which adheres to WADA and USADA
regulations.
"Our partnership with UFC is about committing to the science
that will educate and advocate," said Aurora CEO Terry Booth. "We are going to work together to
change the way people think, to change the industry, and to launch
the first hemp-derived CBD products that are backed by scientific
research. The brand-building and product development are all part
of our move into the U.S., and in collaboration with UFC, and we
intend to play a major role in that market."
"We know anecdotally that professional athletes across sports
disciplines are turning to hemp-derived CBD treatments to assist
with physical recovery, with varying degrees of success," added
Jason Dyck, Chair of Aurora's Global
Scientific Oversight Committee. "The work we do in partnership with
UFC will create an evidence-based, science-backed pipeline of
consistent, and 'clean' hemp-derived CBD topicals that the
high-performance athletes of UFC can rely on to treat the pain,
inflammation, injury and other conditions associated with competing
at such a high level."
"Collaborating with Aurora is the best way to educate ourselves
and our fighters about the impact of CBD on MMA athletes and our
sport," said Dr. Duncan French,
UFC's Vice President of Performance. "We want to apply science and
see where it leads us. Ideally, these studies will give us
the clarity we need to determine n the effectiveness of
hemp-derived CBD on athlete health and injury recovery."
"Although CBD is allowed under USADA and WADA regulations, we
want to be the leaders on educating UFC athletes on CBD use," said
Jeff Novitzky, UFC Senior Vice
President of Athlete Health & Performance. "Athlete
safety is a top priority for UFC, and we will collaborate with
Aurora to ensure that any new products are third-party tested for
all WADA-prohibited substances to make certain they meet WADA
standards."
Download the media kit HERE.
About UFC®
UFC®, is the world's premier mixed martial arts organization and
the largest Pay-Per-View event provider in the world. UFC boasts
more than 300 million fans worldwide, including 70 million social
media followers across all its digital platforms, and its
programming is broadcast in over 170 countries and territories to
one billion TV households worldwide in 40 different languages. UFC
produces more than 40 live events annually and consistently sells
out some of the world's most prestigious arenas. Since 2001, UFC
has been proudly headquartered in Las
Vegas, supported by a network of employees around the world.
UFC's current roster of athletes features more than 590 men and
women representing over 60 countries. UFC FIGHT PASS®, the world's
leading digital subscription service for combat sports, delivers
exclusive live events, thousands of fights on-demand, and original
content to fans around the world. UFC was acquired in 2016 by
global sports, entertainment, and fashion leader Endeavor, along
with strategic investors Silver Lake Partners and KKR, in what is
among the largest transactions in sports history. For more
information, visit UFC.com and follow UFC at Facebook.com/UFC,
Twitter, Snapchat and Instagram: @UFC.
About
Aurora
Headquartered in Edmonton, Alberta,
Canada with funded capacity in excess of 625,000 kg per
annum and sales and operations in 24 countries across five
continents, Aurora is one of the world's largest and leading
cannabis companies. Aurora is vertically integrated and
horizontally diversified across every key segment of the value
chain, from facility engineering and design to cannabis breeding
and genetics research, cannabis and hemp production, derivatives,
high value-add product development, home cultivation, wholesale and
retail distribution.
Highly differentiated from its peers, Aurora has established a
uniquely advanced, consistent and efficient production strategy,
based on purpose-built facilities that integrate leading-edge
technologies across all processes, defined by extensive automation
and customization, resulting in the massive scale production of
high-quality product at low cost. Intended to be replicable and
scalable globally, our production facilities are designed to
produce cannabis of significant scale, with high quality,
industry-leading yields, and low per gram production costs. Each of
Aurora's facilities is built to meet EU GMP standards. EU GMP
certification has been granted to Aurora's first production
facility in Mountain View County, the Aurora River facility in
Bradford, Ontario, and its wholly
owned European medical cannabis distributor Aurora Deutschland.
In addition to the Company's rapid organic growth and strong
execution on strategic M&A, which to date includes 15 wholly
owned subsidiary companies – MedReleaf, CanvasRX, Peloton
Pharmaceutical, Aurora Deutschland, H2 Biopharma, Urban Cultivator,
BC Northern Lights, Larssen Greenhouses, CanniMed Therapeutics,
Anandia, HotHouse Consulting, MED Colombia, Agropro, Borela, ICC
Labs, Whistler, and Chemi Pharmaceutical – Aurora is distinguished
by its reputation as a partner and employer of choice in the global
cannabis sector, having invested in and established strategic
partnerships with a range of leading innovators, including: Radient
Technologies Inc. (TSXV: RTI), Hempco Food and Fiber Inc. (TSXV:
HEMP), Cann Group Ltd. (ASX: CAN), Micron Waste Technologies Inc.
(CSE: MWM), Choom Holdings Inc. (CSE: CHOO), Capcium Inc.
(private), Evio Beauty Group (private), Wagner Dimas (private), CTT
Pharmaceuticals (OTCC: CTTH), Alcanna Inc. (TSX: CLIQ), High Tide
Inc. (CSE: HITI) and EnWave Corporation (TSXV: ENW).
Aurora's Common Shares trade on the TSX and NYSE under the
symbol "ACB", and are a constituent of the S&P/TSX Composite
Index.
For more information about Aurora, please visit our investor
website, investor.auroramj.com
Terry Booth, CEO
Aurora Cannabis Inc.
Forward looking statements
This news release includes statements containing certain
"forward-looking information" within the meaning of applicable
securities law ("forward-looking statements"), including, but not
limited to, statements with respect to the performance of the
Company. Forward-looking statements are frequently characterized by
words such as "plan", "continue", "expect", "project", "intend",
"believe", "anticipate", "estimate", "may", "will", "potential",
"proposed" and other similar words, or statements that certain
events or conditions "may" or "will" occur, and include, but are
not limited to, the successful completion of the
clinical research program and the development and commercialization
of hemp- derived CBD topical products . These statements are
only predictions. Various assumptions were used in drawing the
conclusions or making the projections contained in the
forward-looking statements throughout this news release.
Forward-looking statements are based on the opinions and estimates
of management at the date the statements are made, and are subject
to a variety of risks and uncertainties and other factors that
could cause actual events or results to differ materially from
those projected in the forward-looking statements. The Company is
under no obligation, and expressly disclaims any intention or
obligation, to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as expressly required by applicable law.
Neither TSX, NYSE nor their applicable Regulation Services
Providers (as that term is defined in the policies of the Toronto
Stock Exchange and New York Stock Exchange) accept responsibility
for the adequacy or accuracy of this release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aurora-cannabis-and-ufc-launch-clinical-research-on-use-of-hemp-derived-cbd-products-by-mma-athletes-300890611.html
SOURCE Aurora Cannabis Inc.